全球第二个Bcl-2抑制剂,来自中国。 7月10日,亚盛医药发布公告,公司自研的新型Bcl-2选择性抑制剂“利生妥”(通用名:利沙托克拉)获附条件批准,可用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者。 值得注意的是,这是国内首个获批上市的国产原创Bcl-2抑制剂,也是全球第二个上市的Bcl-2抑制剂。去年...
Source Link全球第二个Bcl-2抑制剂,来自中国。 7月10日,亚盛医药发布公告,公司自研的新型Bcl-2选择性抑制剂“利生妥”(通用名:利沙托克拉)获附条件批准,可用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者。 值得注意的是,这是国内首个获批上市的国产原创Bcl-2抑制剂,也是全球第二个上市的Bcl-2抑制剂。去年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.